Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Pacific Biosciences ( (PACB) ).
On January 30, 2026, Pacific Biosciences of California completed the sale of certain intellectual property and other assets tied to its short-read DNA sequencing technology, including clustering, sequencing reagent and detection technologies, to Illumina Cambridge Limited for $50 million in cash plus the assumption of certain liabilities. After directing 4% of the proceeds to former equity holders of Apton Biosystems in connection with waived milestone obligations from PacBio’s August 2023 acquisition of Apton, the company realized approximately $48.1 million in net cash and received a non-exclusive license back to some of the divested intellectual property, a move that strengthens its balance sheet and clarifies its strategic positioning while reducing future Apton-related payment obligations. PacBio has issued unaudited pro forma financial statements to show the impact of the asset sale on its September 30, 2025 balance sheet and on its 2024 and year-to-date 2025 operating results, providing investors greater visibility into the company’s capital structure and post-transaction financial profile.
The most recent analyst rating on (PACB) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Pacific Biosciences stock, see the PACB Stock Forecast page.
Spark’s Take on PACB Stock
According to Spark, TipRanks’ AI Analyst, PACB is a Neutral.
The score is held down primarily by weak financial performance (large losses, significant cash burn, and a notably weakened balance sheet with high leverage). Offsetting factors include improving operating trends discussed on the earnings call (record consumables, higher non-GAAP gross margin, and reduced cash burn targets) and a neutral-to-slightly improving technical picture, while valuation remains unattractive due to negative earnings and no dividend support.
To see Spark’s full report on PACB stock, click here.
More about Pacific Biosciences
Pacific Biosciences of California is a genomics technology company that develops and sells DNA sequencing platforms and related consumables, with a focus on advanced sequencing technologies including short-read and long-read applications for research and clinical markets.
Average Trading Volume: 8,318,832
Technical Sentiment Signal: Hold
Current Market Cap: $682.3M
See more insights into PACB stock on TipRanks’ Stock Analysis page.